Navigation Links
New hope for treating Alzheimer's Disease: A role for the FKBP52 protein
Date:3/20/2012

New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer's drugs and for detecting the disease before the onset of clinical symptoms.

A study published online today in the Journal of Alzheimer's Disease (1), for the first time demonstrates that the FKBP52 protein, discovered by Prof. Etienne BAULIEU twenty years ago, may prevent hyperphosphorylation of Tau protein, which has been shown to characterise a number of cerebral neurodegenerative diseases, including Alzheimer's Disease (AD).

This work has been carried out by Professor Etienne Baulieu and his research team at Inserm (National Institute for medical research in France) with the support of philanthropists who help the Institut Baulieu, based in France.

Limited research exists on Tau and its role in the development of AD, but it is known that many neurodegenerative diseases are characterised by the deposition of pathological hyperphosphorylated forms of Tau protein, into structures known as 'Tau tangles'. The mechanism of Tau toxicity is unclear and there are currently no drug treatments targeting Tau, nor any biomarkers that predict the risk of a future "Tauopathy". Professor Baulieu decided to focus on Tau abnormalities and was the first to discover in 2010, an interaction between Tau, and the FKBP52 protein (2).

The new research takes his previous research to the next level. It demonstrates a direct correlation between high levels of hyperphosphorylated Tau protein and reduced levels of FKBP52, in brain cells from patients who have died following Alzheimer's Disease, compared with normal brain cells. This suggests that FKBP52 could control the aberrant production of pathogenic Tau. When FKBP52 is reduced in the nerve cells of AD patients, pathogenic Tau is free to accumulate and contribute to the degeneration of brain cells.

In conclusion, early measurement of FKBP52 levels could form the basis of a predictive test for Alzheimer's Disease before the onset of clinical symptoms, and new compounds modulating FKBP52's activity could become the next generation of treatments for the disease.

Commenting on this new research, Professor Baulieu said: "There is still a worrying lack of research into the causes of age-related brain disorders such as Alzheimer's Disease and dementia. I founded the Institut Baulieu, with the aim of being able to treat and even prevent these diseases.

Research on Tau has been very limited, and until recently, I was among the few scientists focusing on Tau pathology. The discovery of the FKBP52 protein is the only 'anti-Tau' perspective so far. Its reduced production in the brains of Alzheimer's patients marks a turning point in understanding this complex disease.

I believe it takes us one step closer to developing an effective treatment and possible predictive tests for the increasing number of people who may develop Alzheimer's Disease in our ageing societies."


'/>"/>

Contact: Kristin Shine
KShine@brunswickgroup.com
44-207-404-5959
IOS Press
Source:Eurekalert

Related biology news :

1. New approach to treating cystic fibrosis lung infection shows promise
2. Commercial aquatic plants offer cost-effective method for treating wastewater
3. Pitt research identifies new target in brain for treating schizophrenia
4. UC Davis discovery offers hope for treating kidney cancer
5. World breakthrough in treating premature babies
6. Studies point to novel target for treating arrhythmias
7. Antibody key to treating variant CJD, scientists find
8. New medications show promise in treating drug-resistant prostate cancer
9. NC State researchers find soy may aid in treating canine cancers
10. New drug shows promise in treating drug-resistant prostate cancer
11. Cold and brown fat raise the prospect of a new method of treating obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):
(Date:6/19/2017)... ... June 19, 2017 , ... ... activities supporting EDETEK’s products including training, implementation, support, and client process and SOP ... role. He has previously held leadership roles for service providers and top-tier pharmaceuticals, ...
(Date:6/16/2017)... ... 16, 2017 , ... Cognition Corporation , a software ... sessions of its “From the Helm” Webinar Series. , The next two ... for design control exercises. Led by David Cronin, Cognition’s CEO, the half-hour public ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, a start-up ... of financing in the amount of $6 million. An investment vehicle affiliated with ... round. , The Series B funding will enable Cybrexa to complete the build-out ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... new guide on how to assemble a lab workstation. The guide outlines the ... include Adam’s Nimbus or Eclipse balance, AVT anti-vibration table, OIML/ASTM certified weights, and ...
Breaking Biology Technology: